Home
HelpTest Code MRDMM Multiple Myeloma Minimal Residual Disease, Flow Cytometry, Bone Marrow
Ordering Guidance
This test should be ordered on patients treated for multiple myeloma to confirm remission has been achieved, annual follow-up of those in remission, or in uncertain remission.
This test should not be ordered on known relapsing patients or at diagnosis. For these situations or if fluorescence in situ hybridization is requested, order either PCPRO / Plasma Cell DNA Content and Proliferation, Bone Marrow or MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow
Shipping Instructions
It is recommended that specimens arrive within 2 days of collection. Collect and package specimen as close to shipping time as possible.
Necessary Information
1. Include patient's disease state (untreated, treated, monoclonal gammopathy of undetermined significance, stable).
2. Indicate if patient is on anti-CD38 therapy.
3. Provide Immunofix information if available.
Specimen Required
Specimen Type: Redirected bone marrow
Container/Tube:
Preferred: Yellow top (ACD solution A or B)
Acceptable: Lavender top (EDTA)
Specimen Volume: 4 mL
Useful For
Detecting low level (minimal residual disease) myeloma cells after therapy.
Method Name
Immunophenotyping for Minimal Residual Disease (MRD)
Reporting Name
Multiple Myeloma MRD by Flow, BMSpecimen Type
Bone MarrowSpecimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Bone Marrow | Ambient (preferred) | 72 hours | |
| Refrigerated | 72 hours |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitabilityReference Values
An interpretive report will be provided.
Day(s) Performed
Preanalytical processing: Monday through Saturday
Results reported: Monday through Friday
Report Available
2 to 4 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker
88185 x 9-Flow Cytometry; additional cell surface, cytoplasmic or nuclear marker
88188-Flow Cytometry Interpretation, 9 to 15 Markers
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MRDMM | Multiple Myeloma MRD by Flow, BM | 93022-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| CK146 | % Minimal Residual Disease (MRD) | 93021-4 |
| CK147 | % Normal Plasma Cells (of total PC) | 93020-6 |
| CK148 | Non-Aggregate Events | 38257-2 |
| CK149 | Total Plasma Cell Events | 93019-8 |
| CK150 | Poly PC Events | 93018-0 |
| CK151 | Abnormal PC Events | 93017-2 |
| 615796 | % B-cell Precursors | 101131-1 |
| 615797 | % Mast Cells | 101130-3 |
| 616082 | Validated Assay Sensitivity | 101129-5 |
| 616083 | Lower Limit of Quantitation (LLOQ) | 87706-8 |
| 615798 | Patient / Sample Theoretical LOQ | 101128-7 |
| CK152 | Final Diagnosis | 74226-2 |
NY State Approved
YesForms
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.